These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 15752239)
1. Genetic factors in end-stage renal disease. Satko SG; Freedman BI; Moossavi S Kidney Int Suppl; 2005 Apr; (94):S46-9. PubMed ID: 15752239 [TBL] [Abstract][Full Text] [Related]
2. Genetic linkage analysis of growth factor loci and end-stage renal disease in African Americans. Freedman BI; Yu H; Spray BJ; Rich SS; Rothschild CB; Bowden DW Kidney Int; 1997 Mar; 51(3):819-25. PubMed ID: 9067916 [TBL] [Abstract][Full Text] [Related]
3. The importance of family history on the development of renal disease. Satko SG; Freedman BI Curr Opin Nephrol Hypertens; 2004 May; 13(3):337-41. PubMed ID: 15073494 [TBL] [Abstract][Full Text] [Related]
4. Role of cytogenetic biomarkers in management of chronic kidney disease patients: A review. Khan Z; Pandey M; Samartha RM Int J Health Sci (Qassim); 2016 Oct; 10(4):576-589. PubMed ID: 27833523 [TBL] [Abstract][Full Text] [Related]
5. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245 [TBL] [Abstract][Full Text] [Related]
6. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial). Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260 [TBL] [Abstract][Full Text] [Related]
7. Evidence for different susceptibility genes for proteinuria and ESRD in type 2 diabetes. Placha G; Canani LH; Warram JH; Krolewski AS Adv Chronic Kidney Dis; 2005 Apr; 12(2):155-69. PubMed ID: 15822051 [TBL] [Abstract][Full Text] [Related]
8. Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes. Patente TA; Mohammedi K; Bellili-Muñoz N; Driss F; Sanchez M; Fumeron F; Roussel R; Hadjadj S; Corrêa-Giannella ML; Marre M; Velho G Free Radic Biol Med; 2015 Sep; 86():16-24. PubMed ID: 25862415 [TBL] [Abstract][Full Text] [Related]
9. Screening for subclinical nephropathy in relatives of dialysis patients. Satko SG; Freedman BI Semin Dial; 2001; 14(5):311-3. PubMed ID: 11679093 [TBL] [Abstract][Full Text] [Related]
10. Family history of end-stage renal disease among hemodialyzed patients in Poland. Gumprecht J; Zychma MJ; Moczulski DK; Gosek K; Grzeszczak W J Nephrol; 2003; 16(4):511-5. PubMed ID: 14696752 [TBL] [Abstract][Full Text] [Related]
12. Genetic factors in diabetic nephropathy. Freedman BI; Bostrom M; Daeihagh P; Bowden DW Clin J Am Soc Nephrol; 2007 Nov; 2(6):1306-16. PubMed ID: 17942768 [TBL] [Abstract][Full Text] [Related]
13. The role of genetic factors in the development of end-stage renal disease. Freedman BI; Bowden DW Curr Opin Nephrol Hypertens; 1995 May; 4(3):230-4. PubMed ID: 7648217 [TBL] [Abstract][Full Text] [Related]
15. The Saudi Diabetic Kidney Disease study (Saudi-DKD): clinical characteristics and biochemical parameters. Al-Rubeaan K; Siddiqui K; Alghonaim M; Youssef AM; AlNaqeb D Ann Saudi Med; 2018; 38(1):46-56. PubMed ID: 29295969 [TBL] [Abstract][Full Text] [Related]
16. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). Iyengar SK; Abboud HE; Goddard KA; Saad MF; Adler SG; Arar NH; Bowden DW; Duggirala R; Elston RC; Hanson RL; Ipp E; Kao WH; Kimmel PL; Klag MJ; Knowler WC; Meoni LA; Nelson RG; Nicholas SB; Pahl MV; Parekh RS; Quade SR; Rich SS; Rotter JI; Scavini M; Schelling JR; Sedor JR; Sehgal AR; Shah VO; Smith MW; Taylor KD; Winkler CA; Zager PG; Freedman BI; Diabetes; 2007 Jun; 56(6):1577-85. PubMed ID: 17363742 [TBL] [Abstract][Full Text] [Related]
17. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Ismail N; Becker B; Strzelczyk P; Ritz E Kidney Int; 1999 Jan; 55(1):1-28. PubMed ID: 9893112 [TBL] [Abstract][Full Text] [Related]
18. Impact of birth weight on familial aggregation of end-stage renal disease. Fan ZJ; Lackland DT; Kenderes B; Krisher J; Freedman BI Am J Nephrol; 2003; 23(2):117-20. PubMed ID: 12481151 [TBL] [Abstract][Full Text] [Related]
19. Familial risk, age at onset, and cause of end-stage renal disease in white Americans. Spray BJ; Atassi NG; Tuttle AB; Freedman BI J Am Soc Nephrol; 1995 Apr; 5(10):1806-10. PubMed ID: 7787148 [TBL] [Abstract][Full Text] [Related]
20. Impact of nitric oxide synthase Glu298Asp polymorphism on the development of end-stage renal disease in type 2 diabetic Egyptian patients. El-Din Bessa SS; Hamdy SM Ren Fail; 2011; 33(9):878-84. PubMed ID: 21854353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]